

22. A fusion immunotoxin according to claim 21, wherein the toxin moiety is a diphtheria toxin moiety.
23. A fusion immunotoxin according to claim 22, wherein the diphtheria toxin moiety is a mutant of native diphtheria toxin which retains toxicity but has reduced binding to non-target cells.
24. A fusion immunotoxin according to claim 23, wherein the diphtheria toxin moiety is a truncation of native diphtheria toxin.
25. A fusion immunotoxin according to claim 24, wherein the diphtheria toxin moiety is a truncation of native diphtheria toxin at the carboxy terminus.
26. A fusion immunotoxin according to claim 25, wherein the diphtheria toxin moiety is DT390.
27. A fusion immunotoxin according to claim 21, wherein the single chain variable region of the anti-CD3 antibody comprises the variable light domain linked to the variable heavy domain, optionally via a linker.
28. A fusion immunotoxin according to claim 27, wherein the single chain variable region of the anti-CD3 antibody consists of the variable light domain linked to the variable heavy domain via a linker.

29. A fusion immunotoxin according to claim 21, wherein the anti-CD3 antibody binds to the CD3ε epitope.
30. A fusion immunotoxin according to claim 28, wherein the anti-CD3 antibody is UCHT1.
31. A fusion immunotoxin according to claim 30, wherein the toxin moiety is DT390.
32. A fusion immunotoxin according to claim 21, comprising DT390 linked via its carboxy terminus, optionally via a linker, to the single chain variable region of an anti-CD3 antibody.
33. A fusion immunotoxin according to claim 32, wherein the single chain variable region of the anti-CD3 antibody comprises the variable light domain linked via its carboxy terminus to the variable heavy domain, optionally via a linker.
34. A fusion immunotoxin according to claim 33, wherein the anti-CD3 antibody is UCHT1.
35. A fusion immunotoxin according to claim 21, comprising DT390 linked via its carboxy terminus, optionally via a linker, to the variable light domain of an anti-CD3 antibody, and wherein the variable light domain region is linked via its carboxy terminus, optionally via a linker, to the variable heavy domain of the anti-CD3 antibody.

36. A fusion immunotoxin according to claim 35, comprising DT 390 linked via a linker to the variable light domain of UCHT1 which is linked via a linker to the variable heavy domain of UCHT1.

Sub
DL 37. A fusion immunotoxin, consisting of DT390 linked via its carboxy terminus through a linker to the variable light domain of UCHT1 which is linked via its carboxy terminus through a (Gly₄Ser)₃ linker to the variable heavy domain of UCHT1.

38. A method for inhibiting rejection of transplanted tissue or organs, comprising administering to a subject in need thereof an immunotoxin according to claim 21.

39. A method for treating an autoimmune disease, comprising administering to a subject in need thereof an immunotoxin according to claim 21.

Sub
DL 40. A method of treating T cell leukemias or lymphomas, comprising administering to a subject in need thereof an immunotoxin according to claim 21.

41. A method of treating graft-versus-host disease, comprising administering to a subject in need thereof an immunotoxin according to claim 21.

42. A method of treating acquired immunodeficiency syndrome, comprising administering to a subject in need thereof an immunotoxin according to claim 21.--

Please delete claims 1-20 without prejudice.